Kurse werden geladen...
Prognose
Kaufen | 1 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -5 / 13 |
News
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY , March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD $1 million. In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics.» Mehr auf prnewswire.com
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
SYDNEY , Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer.» Mehr auf prnewswire.com
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
SYDNEY , Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct offering with existing fundamental healthcare investor, Alumni Capital LP, of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing 100 ordinary shares of the Company, at a purchase price of $1.50 per ADS (or ADS equivalent in lieu thereof) and concurrent private placement of unregistered warrants to purchase up to an aggregate of 1,333,333 ADSs. The warrants will have an exercise price of $1.50 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance.» Mehr auf prnewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 1,54 Mio | - |
Bruttoeinkommen | 1,54 Mio | - |
Nettoeinkommen | −11,16 Mio | - |
EBITDA | −11,59 Mio | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 2,37 Mio€ |
Anzahl Aktien | 3,33 Mio |
52 Wochen-Hoch/Tief | 14,30€ - 0,69€ |
Dividenden | Nein |
Beta | 2,29 |
KGV (PE Ratio) | −0,01 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | −0,04 |
KUV (PS Ratio) | 1,67 |
Unternehmensprofil
Kazia Therapeutics Limited, ein auf die Onkologie spezialisiertes Biotechnologieunternehmen, entwickelt Medikamente gegen Krebs. Der führende Entwicklungskandidat ist Paxalisib, ein niedermolekularer, hirnwirksamer Inhibitor des PI3K/Akt/mTor-Signalwegs, der als potenzielle Therapie für Glioblastome entwickelt wird. Außerdem entwickelt das Unternehmen EVT801, ein neues Prüfpräparat für verschiedene Krebsarten. Das Unternehmen war früher unter dem Namen Novogen Limited bekannt und änderte im November 2017 seinen Namen in Kazia Therapeutics Limited. Kazia Therapeutics Limited wurde 1994 gegründet und hat seinen Sitz in Sydney, Australien.
Name | Kazia Therapeutics SP ADR Aktie |
CEO | Dr. John Edwin Friend II, M.D. |
Sitz | Sydney, nsw Australien |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 9 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | KZIA |
Frankfurt | NV9M.F |
Assets entdecken
Shareholder von Kazia Therapeutics SP ADR Aktie investieren auch in folgende Assets